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The decline in hematopoietic function seen during
aging involves a progressive reduction in the immune
response and an increased incidence of myeloid
malignancy, and has been linked to aging of hemato-
poietic stem cells (HSCs). The molecular mecha-
nisms underlying HSC aging remain unclear. Here
we demonstrate that elevated activity of the small
RhoGTPase Cdc42 in aged HSCs is causally linked
to HSC aging and correlates with a loss of polarity
in aged HSCs. Pharmacological inhibition of Cdc42
activity functionally rejuvenates aged HSCs, in-
creases the percentage of polarized cells in an aged
HSC population, and restores the level and spatial
distribution of histone H4 lysine 16 acetylation to a
status similar to that seen in young HSCs. Our data
therefore suggest a mechanistic role for Cdc42
activity in HSC biology and epigenetic regulation,
and identify Cdc42 activity as a pharmacological
target for ameliorating stem cell aging.
INTRODUCTION
In the hematopoietic system, aging is driven by both intrinsic and
extrinsic factors (Chambers and Goodell, 2007; Dorshkind and
Swain, 2009; Geiger et al., 2005; Geiger and Van Zant, 2002;
Ju et al., 2007; Morrison et al., 1996; Rando, 2006; Rossi et al.,
2005) and manifests as decreased immune response (Linton
and Dorshkind, 2004), increased myelogenous disease (Kiss
et al., 2007; Signer et al., 2007), late-onset anemia (Beghe´
et al., 2004), and reduced regenerative capacity (Ergen and
Goodell, 2009). Multiple studies and our own data demonstrate
that the aged murine hematopoietic system is impaired in sup-
porting peripheral blood (PB) leukocyte numbers (Figure S1A
available online), erythropoiesis (Figures S1B and S1C), and
B-lymphoid and T-lymphoid cells (Figure S1D), while the number
of myeloid cells is increased (Figure S1D). Changes in the
total number of primitive hematopoietic cells with age are
strain dependent (Kamminga et al., 2005) and are at least in520 Cell Stem Cell 10, 520–530, May 4, 2012 ª2012 Elsevier Inc.part intrinsic to hematopoietic stem cells (HSCs). For ex-
ample, in C57BL/6 mice, early hematopoietic progenitor cell
(Lineagenegc-Kit+Sca-1+, or LSK) and long-term repopulating-
HSC (LSKCD34low/Flk2, LT-HSCs) numbers increase with
age (Figures S1E and S1F), while numbers of lymphoid-primed
multipotent progenitors (LMPPs, LSKCD34+Flk2+; Adolfsson
et al., 2005) decrease (Figure S1F). Independent of the strain,
aged HSCs show reduced self-renewal activity as determined
in serial transplant/engraftment assays (Janzen et al., 2006;
Rossi et al., 2005) and exhibit a 2-fold reduced ability to home
to the bone marrow (BM) (Liang et al., 2005). Moreover, aged
LSKs are less efficient in their ability to adhere to stroma cells
and exhibit significantly elevated cell protrusion activity in vivo
(Geiger et al., 2007; Kohler et al., 2009; Xing et al., 2006).
Thus, a defined set of cell-intrinsic phenotypic and functional
parameters separate young from aged HSCs. Due to the cell-
intrinsic component of HSC aging—aged HSCs present with
most of these phenotypes also when exposed to a young micro-
environment—one refers to young HSCs and aged HSCs when
speaking of HSCs from young and aged animals (Geiger and
Rudolph, 2009).
Cdc42 belongs to the family of small RhoGTPases and cycles
between an active (GTP-bound) and an inactive (GDP-bound)
state. Cdc42 is known to regulate actin and tubulin organization,
cell-cell and cell-extracellular matrix adhesion, and cell polarity
in distinct cell types (Cau and Hall, 2005; Etienne-Manneville,
2004; Florian and Geiger, 2010; Sinha and Yang, 2008). Our
previous and current studies demonstrate that Cdc42 activity
is significantly increased in both primitive hematopoietic cells
(Figure S1G) and other tissues of aged mice when compared
with that in cells from young animals (Xing et al., 2006). Based
on this observation we hypothesize that the aging-associated
increased Cdc42 activity in HSCs may causatively regulate
cell-intrinsic aging of HSCs (Geiger et al., 2007; Kohler et al.,
2009).
RESULTS
Constitutively Increased Cdc42 Activity Results
in Aging-like Phenotypes in Young HSCs
To test the role of Cdc42 activity in cell-intrinsic aging of
HSCs, we determined whether Cdc42 activity in young HSCs
Figure 1. Constitutively Increased Cdc42
Activity Results in Premature Aging of
Young HSCs
(A) Scheme of the experimental set-up for the
competitive BM transplants.
(B) Contribution of total donor-derived Ly5.2+ cells
in PB after 20 weeks in competitive primary and
secondary transplants. Percentages of engrafted
cells are normalized according to stem cell equiv-
alent.Mice were considered as engraftedwhen the
percentageof Ly5.2+ cells inPBwashigher than1.0
and contribution was detected for all PB lineages.
(C and D) Contribution of B cells, T cells, and
myeloid cells among donor-derived Ly5.2+ cells in
PB after 20 weeks in competitive primary (C) and
secondary (D) transplants.
(E–G) Representative FACS dot plots (E) and
quantitative and statistical analysis of LT-HSC,
ST-HSC, and LMPP distribution among donor-
derived LSKs in primary (F) and secondary (G)
transplanted mice. *p < 0.05, **p < 0.01, ***p <
0.001; columns are means +1 SE. The experiment
was repeated three times with a cohort of four or
five recipient mice per group (n = 14).
See also Figure S1.
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Hematopoietic Stem Cell Aging and Cdc42constitutively increased by genetic means is sufficient to
resemble aging-like phenotypes in HSCs, using as a model
HSCs deficient for the p50RhoGAP protein (Cdc42GAP/
mice). This RhoGAP protein is a highly selective negative re-
gulator of Cdc42 activity (Barfod et al., 1993), and therefore
Cdc42GAP/ mice present with a gain of activity specific for
Cdc42 in all tissues (Wang et al., 2007), including primitive
hematopoietic cells (Figures S1I). Supporting our hypothesis,
Cdc42GAP/ mice present with premature aging-like pheno-
types in multiple tissues and cell types (Wang et al., 2007). As
for the hematopoietic system, a significant increase in myeloid
cell frequency and a decrease in T cell frequency in PB was
detected in young Cdc42GAP/ mice as well as an overall
decrease of B cell frequency and an increase in myeloid cell
frequency in BM, which are phenotypes consistent with aging inCell Stem Cell 10, 520hematopoiesis (Figure S1J). To determine
the functional status of Cdc42GAP/
HSCs, competitive serial transplant
assayswere performed (Figure 1A), which
are regarded as a gold standard for deter-
mining stem-cell-intrinsic parameters of
HSC aging (Chambers and Goodell,
2007; Rossi et al., 2005, 2008). Results
demonstrated that young Cdc42GAP/
HSCs resemble aged HSCs and were
significantly distinct from young control
Cdc42GAP+/+ HSCs with respect to their
repopulation ability (Figure 1B), contribu-
tion to the B cell lineage, and contribution
to the myeloid cell lineage in PB (Figures
1C and 1D) and BM (Figures S1M and
S1N) inbothprimary andsecondary recip-
ients. Furthermore, young Cdc42GAP/
cells, similarly to aged cells, contributed
significantly more to the pool of LT-HSCscompared with young Cdc42GAP+/+ controls both in primary
and in secondary recipients (Figures 1E–1G). There was also
a significant decrease in the contribution of aged and
Cdc42GAP/ HSCs to LMPPs in secondary recipients
compared with that of young Cdc42GAP+/+ cells (Figure 1G).
Thus, chronologically youngCdc42GAP/HSCsare functionally
similar to chronologically aged HSCs in competitive transplanta-
tion assays. These data imply a mechanistic role for intrinsically
elevated Cdc42 activity in chronologically aged HSCs for pheno-
typic and functional changes associated with aged HSCs.
Increased Cdc42 Activity in HSCs Correlates with
a Depolarized Phenotype in LT-HSCs
In D. melanogaster, the age-associated loss of germline stem
cell function correlates with loss of cell polarity (Cheng et al.,–530, May 4, 2012 ª2012 Elsevier Inc. 521
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Figure 2. Increased Cdc42 Activity Correlates with a Depolarized Phenotype in LT-HSCs
(A) Representative distribution of Cdc42, tubulin, and pericentrin-2 (Per-2) in young LT-HSCs determined by IF. Pictures are shown on a dark background
(panels i, iii, v, and vii) or as overlap with the phase contrast picture (panels ii, iv, vi, and viii). Bar = 5 mm. Panels ix and x show Cdc42 (red) and Per-2 (blue)
distribution over the phase contrast picture. Panel xi: schematic presentation of a representative distribution of Cdc42 in young LT-HSCs (Per-2, blue dot; Cdc42,
red dots). The arrow indicates the direction from ‘‘a’’ to ‘‘b’’ followed for determining fluorescence intensity in panel xii. Panel xii: representative fluorescence
intensity plot obtained by collecting pixel intensity through the section of the cell as indicated in panel xi.
(B) Representative distribution of Cdc42, tubulin, and Per-2 in aged LT-HSCs determined by IF. Pictures are shown on a dark background (panels i, iii, v, and vii) or
as overlap with the phase contrast picture (panels ii, iv, vi, and viii). Bar = 5 mm. Panel ix shows Cdc42 (red) and Per-2 (blue) distribution over the phase contrast
picture. Panel x: schematic presentation of a representative distribution of Cdc42 in aged LT-HSCs (Per-2, blue dot; Cdc42, red dots). The arrow indicates the
direction from ‘‘a’’ to ‘‘b’’ followed for determining fluorescence intensity in panel xi. Panel xii: representative fluorescence intensity plot obtained by collecting
pixel intensity through the section of the cell as indicated in panel x.
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Hematopoietic Stem Cell Aging and Cdc422008). We recently reported a reduction in the frequency of cells
with a polar distribution of microtubules among aged early
hematopoietic progenitor cells (LSK cells) (Kohler et al., 2009).
Cdc42 activity has been implicated in the regulation of polarity
in fibroblasts and epithelial cells (Cau and Hall, 2005; Iden and
Collard, 2008) and in the maintenance of polarity and stemness
in neuronal stem cells (Cappello et al., 2006). Prompted by these
observations we next investigated whether the polarity status of
LT-HSCs changes upon aging, and whether Cdc42 activity
might be causally involved in regulating such changes. To test
this we initially determined the localization of Cdc42, which in it-
self is a cell polarity marker (Etienne-Manneville, 2004), and
tubulin in LT-HSCs in single-cell immunofluorescence (IF) anal-
yses performed on LT-HSCs. Interestingly, in the majority of
young LT-HSCs, Cdc42 and tubulin were asymmetrically distrib-
uted and were found at the same location inside the cell (Figures
2A and 2C, Figures S2A and S2C, and Movie S1). This highly
asymmetric localization of Cdc42 and tubulin did not correlate
with the side of the cell bound to the substrate or with an uneven
distribution of the whole cytoplasm, because, for example,
F-actin always showed a cortical and unpolarized distribution
(Figures S2E and S2F and Movie S2). The asymmetry was
oriented along the xy plane on one side of the nucleus, where
the centrosome was also localized (Figure 2A panels ix–xii and
Movie S1). Therefore, in young LT-HSCs, Cdc42 and the
microtubules were highly concentrated in the immediate peri-
centriolar zone and in the cytoplasmatic space along the
nucleus/centrosome/cell membrane axis (Figures 2A and 2D,
Movie S1). In contrast, Cdc42 and tubulin were distributed
throughout the cell body in an unpolarized fashion in aged
LT-HSCs (Figures 2B and 2C, Figures S2B, S2D, and S2F, and
Movie S3), and the centrosome was mostly found in the middle
of the cell, oriented perpendicularly to the nucleus along the z
axis (Figure 2B panels ix–xi, Figure 2D, and Movie S3). Similar
results (young HSCs polar, aged HSCs apolar) were also ob-
tained by analyzing additional established cell polarity markers
like Crumbs3 (Figures S2G, S2I, and S2J) and Dgl (Figures
S2G and S2K). Par6 (Figures S2G and S2L) and the aPKCz (Fig-
ure S2G) did not follow this pattern, in agreement with recently
published data (Sengupta et al., 2011). Interestingly, the differ-
ence in polarity among young and aged primitive hematopoietic
cells is specific to LT-HSCs because, for example, we did not
observed a difference between young and aged short-term
(ST)-HSCs (Figure S2H), and it is not correlated to the cycle
status, because young and aged LT-HSCs show very similar
cell cycle parameter profiles (Figure S1H and also Chambers
et al., 2007; Rossi et al., 2007; Silva and Conboy, 2008; Sudo
et al., 2000). In summary, chronologically young HSCs present
with a polarity phenotype similar to the one previously described
for memory T cells (Chang et al., 2007; Ludford-Menting et al.,(C) Percentage of young and aged LT-HSC cells with a polar distribution of Cdc42
in total. *p < 0.001.
(D) Percentage of Per-2 polarized cells of Cdc42-polarized young and aged LT-
positive when Per-2 was found at the Cdc42 pole. Shown are means +1 SE, n =
(E) Representative distribution of Cdc42 and tubulin in young Cdc42GAP+/+ and C
or as overlap with the phase contrast picture (panels vii and viii). Bar = 5mm.
(F) Percentages of young Cdc42GAP+/+ (WT Control) and Cdc42GAP/ LT-HSC
n = 4, 200–300 cells scored per sample in total. **p < 0.01, *p < 0.05.
See also Figure S2 and Movies S1–S3.2005)—which is lost upon aging of LT-HSCs. Recently CD150
expression was described as a marker for functionally distinct
subpopulations within the pool of LT-HSCs (Beerman et al.,
2010). The polarity phenotype identifying phenotypically dif-
ferent types of LT-HSCs (polar versus apolar) might thus con-
stitute another surrogate marker for the distinct cell subsets
stained by CD150 expression. The frequency of young LT-
HSCs polarized for Cdc42 and tubulin though was independent
of the expression of CD150 on LT-HSCs (Figures S2M and S2N).
Consistent with a critical role of elevated Cdc42 activity in age-
associated phenotypes like apolarity, IF staining revealed that
the majority of chronologically young Cdc42GAP/ LT-HSCs,
which functionally resemble aged LT-HSCs, were apolar with
respect to Cdc42 and tubulin distribution (Figures 2E and 2F).
In addition, consistent with our observations comparing chrono-
logically young and aged LT-HSCs (Figure S1H), young
Cdc42GAP+/+, Cdc42GAP/ and aged LT-HSCs present
with a similar cell cycle and apoptosis profile (Figures S1K
and S1L), strongly implying that differences in polarity are inde-
pendent of these parameters. These data thus identify Cdc42
as a polarity protein in LT-HSCs showing distinct polarity pheno-
types in young and aged LT-HSCs, and support at a role for
Cdc42 activity specifically in the regulation of LT-HSC polarity.
Pharmacological Reduction of Cdc42 Activity
Rejuvenates Aged LT-HSC Function and Restores
the Level and the Spatial Distribution of Histone H4
Lysine 16 Acetylation
Our data imply that the aging-associated increase in Cdc42
activity might be a stem-cell-intrinsic molecular mechanism
resulting in both apolarity and impaired function of LT-HSCs
with age. We consequently reasoned that inhibiting Cdc42
activity in aged LT-HSCs to the level in young LT-HSCs by phar-
macological means might be a possible approach to at least in
part revert apolarity as well as the impaired function of aged
LT-HSCs. To exclude stem-cell-extrinsic effects and focus on
cell-intrinsic mechanisms, LT-HSCs from aged mice were
treated in vitro with a selective Cdc42 activity inhibitor (Sakamori
et al., 2012) (newly termed CASIN, referred to in Peterson et al.,
2006 as Pirl1-related compound 2) (Y.Z., data not shown, for
structure and specificity of CASIN). Treatment with CASIN
(5mM) reduced the elevated level of active Cdc42 observed in
aged primitive hematopoietic cells to the level observed in young
cells (Figures 3A and 3B). CASIN treatment did not alter cell cycle
status or apoptosis in aged LT-HSCs (Figures S3A–S3C). In
response to treatment with CASIN, LT-HSCs from aged mice
showed a dose-dependent increase in the percentage of polar-
ized cells, becoming progressively indistinguishable from young
cells (Figures 3C and 3D). These data demonstrate that elevated
Cdc42-GTP levels in aged LT-HSCs cell-intrinsically regulateand tubulin. Shown aremeans +1SE, n = 10;500–700 cells scored per sample
HSCs. Cdc42-polarized cells were analyzed for Per-2 localization and scored
4, 150–250 cells scored per sample in total. *p < 0.05.
dc42GAP/ LT-HSCs. Pictures are shown on a dark background (panels i–vi)
cells with a polar distribution of Cdc42 and tubulin. Shown are means +1 SE,
Cell Stem Cell 10, 520–530, May 4, 2012 ª2012 Elsevier Inc. 523
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Figure 3. Pharmacological Targeting of
Cdc42 Reverts Aged Apolar LT-HSCs to
Polar Cells
(A) Representative Cdc42 activity in young, aged,
and CASIN (5mM)-treated aged lineage depleted
bone marrow (Lin–BM) as determined by a pull-
down/western blot assay. Active Cdc42 (Cdc42-
GTP) was normalized with respect to total Cdc42
and actin as delineated by the numbers.
(B) Ratio of the densitometric score of the
Cdc42-GTP form and the total Cdc42 expression.
Shown are means +1 SE, n = 3, xp < 0.05 versus
young control; *p < 0.05 versus aged control.
(C) Representative distribution of Cdc42, tubulin,
and Per-2 in young, aged, and aged LT-HSCs
treated with 5mMCASIN. Shown are overlaps with
the phase contrast picture (panels i–iii) or cells on
a dark background (panels iv–xv). Bar = 5 mm.
(D) Percentages of cells polarized for Cdc42 and
tubulin in young, aged, and aged LT-HSCs treated
with 2.5 and 5mM CASIN. For each sample
cells were singularly analyzed and scored for
Cdc42 and tubulin polar distribution. Shown are
means +1 SE, n = 4, 200–300 cells scored per
sample in total. xp < 0.001 versus young control;
***p < 0.001 versus aged control, **p < 0.01 versus
aged control, *p < 0.05 versus aged control.
See also Figure S3.
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Hematopoietic Stem Cell Aging and Cdc42both Cdc42 and tubulin distribution and that the apolar dis-
tribution of these proteins can be reverted to a polar one by
decreasing Cdc42 activity. Thus, CASIN treatment reverted
aged LT-HSCs to young HSCs with respect to the polarity
phenotype.
We next determined whether inhibition of Cdc42 activity in
aged LT-HSCs via CASIN treatment could revert at least in
part the altered function of aged LT-HSCs tomake thembecome
functionally younger. Although CASIN acts transiently on Cdc42
activity, surprisingly, the increase in the percentage of polar cells
among aged LT-HSCs induced by CASIN in vitro remained
stable for at least up to 6 hr after CASIN withdrawal (Figures
S3D and S3E). This result implies a kind of ‘‘polarity memory’’
upon transient reduction of Cdc42 activity in aged LT-HSCs,
which might allow continuation of the new polar phenotype
and the associated function or functions upon transplantation
into recipient animals. Therefore, 200 aged LT-HSCs treated
with 5mM CASIN overnight were competitively serially trans-
planted into young recipients and compared to transplants
with young and aged untreated LT-HSCs (Figure 4A). In primary
recipients, overall donor engraftment after 8, 16, and 24 weeks524 Cell Stem Cell 10, 520–530, May 4, 2012 ª2012 Elsevier Inc.was similar in aged control and aged
CASIN-treated LT-HSCs (Figure 4B),
but remarkably, CASIN treatment of
aged LT-HSCs resulted in an increase in
contribution to the B cell compartment
in PB and a reduced contribution to the
myeloid lineage (Figure 4D). In addition,
CASIN treatment increased the con-
tribution to LSK and common lymphoid
progenitor (CLP) populations to a level
indistinguishable from that of young LT-HSCs (Figure S4A). The frequency of donor-derived LT-HSCs
among donor-derived LSKs was, as anticipated, doubled in
aged control recipients, while upon CASIN treatment this fre-
quency was significantly reduced (Figure 4F). In addition, upon
secondary transplant, CASIN-treated LT-HSCs presented with
an elevated overall regenerative capacity compared with aged
LT-HSCs, as indicated by increased and stable chimerism in
PB (Figure 4C). Moreover, upon secondary transplant, CASIN-
treated aged LT-HSCs proved to be indistinguishable from
young LT-HSCs with respect to B cell and myeloid engraftment
in PB and BM (Figure 4E and Figures S4B and S4C) and with
respect to the contribution to the LT-HSC pool in BM (Figure 4G).
Young CASIN-treated LT-HSCs that were competitively trans-
planted in experiments alongside the aged control and aged
CASIN-treated LT-HSCs transplants did not show any relevant
functional changes compared with young control LT-HSCs (Fig-
ures S4D–S4K), demonstrating that CASIN reverts specifically
aging-related phenotypes of aged LT-HSCs.
Because aged HSCs exhibit a 2-fold reduced ability to home
to the BM (Dykstra et al., 2011; Liang et al., 2005) and aged early
hematopoietic progenitor cells localize more distantly from the
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Figure 4. Pharmacological Targeting of Cdc42 Activity Rejuvenates LT-HSC Function
(A) Schematic representation of the experimental setup. Two-hundred aged and young donor (Ly5.2+) LT-HSCs were cultured for 16 hr as indicated and
subsequently transplanted into recipient (Ly5.1+) mice along with 33 105 BM competitor (Ly5.1+) cells. Twenty-four weeks after transplant, recipient mice were
sacrificed and secondary transplants were performed.
(B and D) Percentage of donor contribution (Ly5.2+ cells) to total WBC in PB 8, 16, and 24weeks after transplant in primary (B) and secondary (D) transplants.Mice
were considered as engrafted when the percentage of Ly5.2+ cells in PBwas greater than 1.0 in primary transplants and greater than 0.5 in secondary transplants
and contribution was detected for all PB lineages. Shown are mean values +1 SE; **p < 0.01 and *p < 0.05 versus young control in (B); ***p < 0.001, **p < 0.01,
*p < 0.05 versus aged control in (D).
(C and E) Percentage of B220+, CD3+, and myeloid cells among donor-derived Ly5.2+ cells in PB 24 weeks after primary (C) and secondary (E) transplants.
*p < 0.05, **p < 0.01, ***p < 0.001; shown are mean values +1 SE.
(F and G) Percentage of LT-HSC, ST-HSC, and LMPP cells in BM among donor-derived LSKs cells 24 weeks after primary (F) and secondary (G) transplants.
**p < 0.01; shown are mean values +1 SE. Data is based on five (primary transplants) and four (secondary transplants) experimental repeats with five recipient
mice per group (e.g., n = 25 for primaries and n = 20 for secondary transplants).
(H) Representative distribution of Cdc42, tubulin, and Per-2 in donor-derived LT-HSCs sorted from young, aged, and aged CASIN-treated LT-HSC recipient mice
24 weeks after transplant. Shown are overlaps with the phase contrast picture (panels i–iii) or cells on a dark background (panels iv–xv). Bar = 5 mm.
(I) Percentage of donor-derived LT-HSCs polarized for Cdc42 and tubulin sorted 24weeks after transplant from recipient animals competitively reconstitutedwith
young, aged, and aged CASIN-treated LT-HSCs. Shown are mean values +1 SEM, n = 3, 50 cells scored per sample in total. **p < 0.01, *p < 0.05.
See also Figure S4.
Cell Stem Cell
Hematopoietic Stem Cell Aging and Cdc42endosteum compared with the localization of young cells (Kohler
et al., 2009), we next investigated whether these aging-associ-
ated phenotypes were also rejuvenated by CASIN treatment.
Homing of young, aged, and aged CASIN-treated LT-HSCs
was determined in competitive short-term homing assays
(Dykstra et al., 2011) (Figure S5A), while the distance of LT-
HSCs from the endosteum was measured by intravital two-
photon microscopy (Kohler et al., 2009). The data indicate thatCASIN-treated aged LT-HSC present with significantly improved
homing to the BM and localize closer to the endosteum (Figures
S5B–S5F) compared with aged control LT-HSCs.
Finally, the frequency of polar donor-derived LT-HSCs in
recipients transplanted with aged, aged CASIN-treated, and
young primary LT-HSCs was determined 24 weeks after trans-
plantation. The data indicate that the percentage of donor-
derived polar LT-HSCs in recipients transplanted with agedCell Stem Cell 10, 520–530, May 4, 2012 ª2012 Elsevier Inc. 525
Figure 5. Pharmacological Targeting of Cdc42 Activity Restores the Level and the Spatial Distribution of Histone H4 Lysine 16 Acetylation
(A) Representative FACS density plots of AcH4K16 expression in LT-HSCs, ST-HSCs, and LMPPs. Aged LT-HSCs distribute in two distinct subpopulations
expressing low and high AcH4K16 levels.
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Hematopoietic Stem Cell Aging and Cdc42CASIN-treated LT-HSCs was similar to the frequency found in
young controls, and significantly increased, at least with respect
to Cdc42 localization, compared with the frequency found in
aged untreated controls (Figures 4H and 4I).
One explanation for the long-lasting ‘‘memory effect’’ on aged
LT-HSCs upon transient reduction of Cdc42 activity observed in
our experiments might be that reduction of Cdc42 activity to
the level seen in young LT-HSCs results in epigenetic marker
changes in aged LT-HSCs, accordingly with a proposed role
for epigenetic regulation of stem cell aging (Pollina and Brunet,
2011; Rando and Chang, 2012). Acetylation of histones is a prev-
alent epigenetic chromatin modification in eukaryotes. Activated
Cdc42was reported to specifically alter acetylation of histoneH4
in 3T3 cells (Alberts et al., 1998), and histone H4 acetylation has
been shown to be mitotically stable and inheritable during devel-
opment (Cavalli and Paro, 1999). On histone H4, lysine 16 is the
most common site of acetylation, and controls chromatin struc-
tures as well interactions between nonhistone proteins and chro-
matin fibers, while it is unique as it is the only lysine residue
among N-terminal tails of all histones targeted by the Sir2 (or
class III) family of HDACs (Vaquero et al., 2007). Histone H4
lysine 16 acetylation (AcH4K16) has been implicated in regu-
lating yeast replicative aging (Dang et al., 2009), and AcH4K16
levels were found to be reduced in multiple tissues of aged
mice (Krishnan et al., 2011).
Consequently, we investigated whether elevated Cdc42
activity might affect histone H4 acetylation levels as well as
specifically AcH4K16 patterns in primitive hematopoietic cells
including LT-HSCs. Our data demonstrate that young LT-HSCs
express higher levels of AcH4K16 than young ST-HSCs and
LMPPs do (Figures 5A and 5D), in agreement with previous
reports (Chung et al., 2009). Aged LT-HSCs present with an
overall decreased level of AcH4K16 compared with young LT-
HSCs, but still show higher levels of AcH4K16 compared with
aged ST-HSCs and LMPPs (Figures 5A and 5D). Moreover,
aged LT-HSCs only present with two distinct subpopulations ex-
pressing low and high AcH4K16 levels (Figure 5A), which are not
found in young LT-HSCs. Young LT-HSCs are almost exclusively
AcH4K16high cells while 34% of aged LT-HSCs present with a
lowAcH4K16 expression level. CASIN treatment induces a sharp
decrease of the frequency of AcH4K16low aged LT-HSCs while
increasing the frequency of AcH4K16high cells (Figures 5A–5C).
This effect of CASIN on AcH4K16 (Figures 5A–5D) was specific
to LT-HSCs (no effect on ST-HSCs and LMPPs), age specific
(young CASIN-treated LT-HSCs did not display any significant
modification), and specific to acetylation of lysine 16 on histone
H4 (the total level of acetylation on histone H4 was not altered;(B and C) Percentage of LT-HSCs expressing low (B) and high (C) levels of AcH4
(D and E) Median fluorescence intensity detected for AcH4K16 (D) and total AcH4
*p < 0.05.
(F) Representative distribution of AcH4K16 (red) and tubulin (green) in young, ag
(blue). Bar = 5 mm. Schemes of tubulin and AcH4K16 distributions in young, aged,
plot obtained by collecting pixel intensity through the section of the relative cell
(G) Percentages of cells polarized for AcH4K16 and tubulin in young, aged, and
analyzed and scored for AcH4K16 and tubulin polar distribution. The percentage
(H) Percentages of cells polarized for AcH4K16 and tubulin in opposite poles in y
showing opposite polarity is plotted over the number of cells polarized for both m
total. *p < 0.01.
See also Figure S5 and Movies S4 and S5.Figure 5E). Most interestingly, we observed that AcH4K16 local-
ization within the nucleus of young LT-HSCs was polarized and
opposite that of the cytoplasmatic tubulin pole, while the great
majority of aged LT-HSCs nuclei were apolar for AcH4K16 local-
ization (Figures 5F–5H and Movies S4 and S5). Strikingly, CASIN
treatment of aged LT-HSCs increased the frequency of aged
LT-HSCs with a polar localization of AcH4K16 to a level similar
to that found in young LT-HSCs (Figures 5F–5H). Thus treatment
of aged LT-HSCs with CASIN restores the level and the spatial
distribution of AcH4K16 to the level seen in young LT-HSCs,
consistent with a previous suggested loss of epigenetic regula-
tion in aged HSCs (Chambers et al., 2007; Pollina and Brunet,
2011). Importantly, our data does not exclude the possibility
that inhibition of Cdc42 activity in aged LT-HSCsmight also alter
additional epigenetic marks like histone methylation patterns.
In summary, these data identify elevated Cdc42 activity as a
key modulator of a molecular pathway driving intrinsic mecha-
nisms of stem cell aging. Furthermore, these results demon-
strate that lowering Cdc42 activity by CASIN treatment rejuve-
nates aged LT-HSCs with respect to function (lineage skewing,
regenerative capacity, and homing) and phenotypic (polarity)
and epigenetic (AcH4K16, both level of acetylation and localiza-
tion within the nucleus) parameters.
DISCUSSION
Until recently, there was a broad consensus that the phenotype
of aged HSCs is fixed and dominated by cell-intrinsic regulatory
mechanisms that could not be reverted by therapeutic interven-
tion. This paradigm recently started to shift (Rando and Chang,
2012), because it was demonstrated that impaired contribution
to PB upon transplantation of aged HSCs could be ameliorated
by either antioxidative therapy or rapamycin treatment (Chen
et al., 2009; Ito et al., 2006). Our data significantly extend these
observations as we demonstrate a critical mechanistic role
of Cdc42 activity in HSC aging and identify it as a target for phar-
macological rejuvenation of stem-cell-intrinsic age-associated
phenotypes of LT-HSCs. Also, because the differences in
polarity between young and aged LT-HSCs with respect to
Cdc42, tubulin, and AcH4K16 are regulated by Cdc42 activity,
these data further support a novel concept in which aging-
associated changes in LT-HSC self-renewal and differentiation
are possibly regulated by changes in stem cell polarity. Our
data further identify a role for Cdc42 activity in regulating epige-
netic modifications in LT-HSCs and polarity of epigenetic
markers (epi-polarity), and identify the loss of this polarity upon
aging as a key concept in HSC biology. Interestingly, a recentK16 according to the gating shown in (A).
(E) in LT-HSCs, ST-HSCs, and LMPPs. Shown are mean values +1 SEM, n = 3.
ed, and aged LT-HSCs treated with 5mM CASIN. Nuclei are stained with DAPI
and aged LT-HSCs treated with 5mMCASIN and relative fluorescence intensity
are also shown.
aged CASIN-treated (5mM) LT-HSCs. For each sample cells were singularly
of polarized cells is plotted over the total number of cells scored.
oung, aged, and aged CASIN-treated (5mM) LT-HSCs. The percentage of cells
arkers. Shown are means +1 SE, n = 3, 100–150 cells scored per sample in
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Hematopoietic Stem Cell Aging and Cdc42report described a prominent role for epigenetic modifications in
transgenerational and thus long-term-memory-associated
longevity in C. elegans (Greer et al., 2011). Furthermore,
genome-wide association studies have recently identified a posi-
tive correlation betweenCdc42 expression in humanwhite blood
cells and increased morbidity and aging (Kerber et al., 2009),
while elevated Cdc42 activity was found in multiple tissues of
aged mice, likely implying a role for the Cdc42-polarity pathway
in aging not only of LT-HSCs.EXPERIMENTAL PROCEDURES
Serial Competitive Transplantation
BM cells (106) from 4- to 6-week-old Cdc42GAP+/+ and Cdc42GAP/ mice
and aged (20- to 26-month-old) C57BL/6 mice (donors, Ly5.2+) were mixed
with 106 BM cells from young (2- to 4-month-old) BoyJ competitor mice
(Ly5.1+) and injected into the retro-orbital sinus of irradiated BoyJ recipient
mice (Ly5.1+) in 200 ml in PBS. Primary transplanted mice were sacrificed after
20 weeks and 2 3 106 BM cells from each recipient mouse were injected into
a secondary preconditioned recipient BoyJ mouse. Serial BM transplantation
experiments were repeated three times with a cohort of four or five recipient
mice per donor. For competitive LT-HSC transplantation, young (2- to
4-month-old) and aged (20- to 26-month-old) C57BL/6 mice (Ly5.2+) were
used as donors. Two-hundred LT-HSCs were sorted into 96 multiwell plates
and cultured (either in suspensionor adherent to fibronectin) for 16 hr inHBSS+
10% FBS ± CASIN (5mM) in a water-jacketed incubator at 37C (5% CO2, 3%
O2). Stem cells were then mixed with 3 3 10
5 BM cells from young (2- to
4-month-old) BoyJ competitor mice (Ly5.1+) and then transplanted into BoyJ
recipient mice (Ly5.1+). PB chimerism was determined by FACS analysis every
8 weeks. Twenty-four weeks after primary transplants, 2 3 106 BM cells from
an individual primary recipient mouse were injected into an individual
secondary preconditioned recipient BoyJ mouse. Experiments were per-
formed three times with LT-HSCs cultured in suspension and two times with
LT-HSCs cultured on a fibronectin-coated substrate without any difference
in experimental outcome. Primary transplanted mice were regarded engrafted
when PB chimerism was greater or equal to 1.0% and contribution was
detected in all lineages. Secondary transplanted mice were regarded as
engrafted when PB chimerism was greater or equal to 0.5% and contribution
was detected in all lineages.
Flow Cytometry and Cell Sorting
PB and BM cell immunostaining was performed according to standard
procedures, and samples were analyzed on an LSRII flow cytometer (BD
Biosciences). Lineage FACS analysis data are plotted as the percentages of
B220+, CD3+, and Myeloid (Gr-1+, Mac-1+, and Gr-1+Mac-1+) cells among
donor-derived Ly5.2+ cells. As for early hematopoiesis analysis, mononuclear
cells were isolated by low-density centrifugation (Histopaque 1083, Sigma)
and stained with a cocktail of biotinylated lineage antibodies. After lineage
depletion by magnetic separation (Dynalbeads, Invitrogen), cells were stained
with anti-Sca-1 (clone D7) (eBioscience), anti-c-Kit (clone 2B8) (eBioscience),
anti-CD34 (clone RAM34) (eBioscience), anti-CD127 (clone A7R34) (eBio-
science), anti-Flk2 (clone A2F10) (eBioscience), and Streptavidin (eBio-
science). Early hematopoiesis FACS analysis data were plotted as the
percentage of LT-HSC (gated as LSK CD34–/lowFlk2–), ST-HSC (gated as
LSK CD34+Flk2–), and LMPP (gated as LSK CD34+Flk2+) (Adolfsson et al.,
2005) distribution among donor-derived LSKs (Linc-Kit+Sca-1+ cells). LSK
and CLPs (gated as Linc-Kit+/lowSca-1+/lowIL7Ra+) (Karsunky et al., 2008)
were plotted as percentages among donor-derived Lin cells. In order to
isolate LT-HSCs, lineage depletion was performed to enrich for lineage-nega-
tive cells. Lineage-negative cells were then stained as aforementioned and
sorted using a BD FACS Aria I or a BD FACS Aria III (BD Bioscience). For intra-
cellular flow cytometric staining of AcH4 and AcH4K16, lineage-depleted
young and aged BM cells were incubated for 16 hr with or without CASIN
(5mM) in IMDM + 10% FBS at 37C (5%CO2, 3%O2). At the end of the treat-
ment, the samples were moved on ice and stained again with the cocktail
of biotinylated lineage antibodies. After being washed the samples were528 Cell Stem Cell 10, 520–530, May 4, 2012 ª2012 Elsevier Inc.stained with anti-Sca-1 (clone D7) (eBioscience), anti-c-Kit (clone 2B8)
(eBioscience), anti-CD34 (clone RAM34) (eBioscience), anti-Flk2 (clone
A2F10) (eBioscience), and Streptavidin (eBioscience). At the end of the surface
staining, cells were fixed and permeabilized with Cytofix/Cytoperm Solution
(BD Biosciences) and incubated with 10% Donkey Serum (Sigma) in BD
Perm/Wash Buffer (BD Biosciences) for 30 min. Primary and secondary
antibody incubations were performed at room temperature in BD Perm/
Wash Buffer (BD Biosciences) for 1 hr and 30 min, respectively. The pri-
mary antibodies for AcH4 were obtained all by Upstate-Millipore (rabbit
anti-acetyl-histone H4 Lys5, Lys8, Lys12, and Lys16). The secondary antibody
is a donkey anti-rabbit DyLight649 (BioLegend).
IF Staining
Freshly sorted LT-HSCs were seeded on fibronectin-coated glass coverslips
in HBSS + 10%FBS. CASIN (referred to in Peterson et al., 2006 as Pirl1-related
compound 2) was obtained from Chembridge Corporation, and purified to
greater than 99% by high-performance liquid chromatography. After 16 hr of
incubation at 37C (5% CO2, 3% O2) in growth factors-free medium, cells
were fixed with BD Cytofix Fixation Buffer (BD Biosciences). After fixation cells
were gently washed with PBS, permeabilized with 0.2% Triton X-100 (Sigma)
in PBS for 20 min, and blocked with 10% Donkey Serum (Sigma) for 30 min.
Primary and secondary antibody incubations were performed for 1 hr at
room temperature. Coverslips were mounted with ProLong Gold Antifade
Reagent with or without DAPI (Invitrogen, Molecular Probes). The cells were
coimmunostained with an anti-alpha tubulin antibody (Abcam, rat monoclonal
ab6160) detected with an anti-rat AMCA-conjugated secondary antibody or an
anti-rat DyLight488-conjugated antibody (Jackson ImmunoResearch), an
anti-Cdc42 antibody (Millipore, rabbit polyclonal) or an anti-AcH4K16 antibody
(Upstate-Millipore, rabbit polyclonal) detected with an anti-rabbit DyLight549-
conjugated antibody (Jackson ImmunoResearch), and/or an anti-Pericentrin-2
antibody (Santa Cruz Biotechnology, goat polyclonal) detected with an
anti-goat AMCA-conjugated antibody (Jackson ImmunoResearch). Samples
were imaged with an AxioObserver Z1 microscope (Zeiss) equipped with
a 633 PH objective. Images were analyzed with AxioVision 4.6 software. Alter-
natively, samples were analyzed with an LSM710 confocal microscope (Zeiss)
equipped with a 633 objective. Primary raw data were imported into the
Volocity Software package (Version 6.0, Perkin Elmer) for further processing
and conversion into 3D images. As for polarity scoring, the localization of
each single-stained protein was considered polarized when a clear asym-
metric distribution was visible by drawing a line across the middle of the
cell. A total of 50 to 100 LT-HSCs were singularly analyzed per sample. Data
are plotted as percentage of the total number of cells scored per sample.
Specificity of the anti-Cdc42 antibody in IF was tested on LT-HSCs sorted
from mice in which Cdc42 was targeted and deleted specifically in the hema-
topoietic system (Mx1-Cre;Cdc42flox/flox mice; Yang et al., 2007) (data not
shown).
Competitive Short-Term Homing Assay and Intravital Two-Photon
Microscopy
For competitive short-term homing assay (Dykstra et al., 2011), LT-HSCs were
sorted from young and aged mice and incubated for 16 hr in HBSS + 10%
FBS ± CASIN (5mM) in a water-jacketed incubator at 37C (5% CO2, 3% O2).
After treatment, LT-HSCs were labeled with the cell tracker CFSE
(Invitrogen-Molecular probes) or the cell tracker CMRA (Invitrogen-Molecular
probes), washed, and mixed, so that 5,000 young + 5,000 aged LT-HSCs or
5,000 aged + 5,000 aged CASIN-treated LT-HSCs could be injected into
each lethally irradiated young recipient mouse (figure S4L). After 16–18 hr
from the stem cell injection, recipient mice were sacrificed and all BM cells
were analyzed by flow cytometry so we could quantify relative frequency of
CFSE+ and CMRA+ cells. A total of six recipient mice were injected per exper-
iment (three receiving 5,000 CFSE+ young LT-HSCs mixed with 5,000 CMRA+
aged LT-HSCs each, and three receiving 5,000 CFSE+ aged CASIN-treated
LT-HSCs mixed with 5,000 CMRA+ aged LT-HSCs each), and the experiment
was repeated twice. For intravital two-photon microscopy analysis, LT-HSCs
were sorted, treated, labeled, and mixed as aforementioned but injected into
nonirradiated recipient young mice. A total of four recipient mice were injected
per experiment (two receiving 5,000 CFSE+ young LT-HSCs mixed with
5,000 CMRA+ aged LT-HSCs each, and two receiving 5,000 CFSE+ aged
Cell Stem Cell
Hematopoietic Stem Cell Aging and Cdc42CASIN-treated LT-HSCs mixed with 5,000 CMRA+ aged LT-HSCs each). After
16–18 hr from the stem cell injection, recipientmice were prepared for intravital
microscopy as previously described (Kohler et al., 2009) using isofluran-based
intubation narcosis. Briefly, the tibiaewere exposed and part of the bone tissue
was carefully removed with an electric drill (Dremel) to obtain a very thin
(30–50 mm) remaining layer of bone tissue covering the BM cavity. This proce-
dure was permanently controlled by stereomicroscopy. The bone tissue was
identified due to its strong autofluorescence (CCD) under unaltered light condi-
tions or using its second-harmonic (SHG) signal (PMT). Animals were kept at
37C in a PBS water bath while experiments were performed. For imaging,
the area was scanned down to120 mm depth (more than 12 cell layers) using
an illumination wavelength of either 800 or 880 nm detecting CFSE (530 nm)
and CMRA (580 nm) fluorescence, as well as unaltered light or SHG
(at 480 nm emission). Primary raw data were imported into the Volocity
Software package (Version 6.0, Perkin Elmer) for further processing and
conversion into 3D images and for measurement of the distance between
LT-HSCs and the endosteum.SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes five figures, five movies, and
Supplemental Experimental Procedures and can be found with this article
online at doi:10.1016/j.stem.2012.04.007.
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